These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 9523734

  • 1. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
    Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F.
    Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
    [Abstract] [Full Text] [Related]

  • 2. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
    Caserini C, Pratesi G, Tortoreto M, Bedogné B, Carenini N, Supino R, Perego P, Righetti SC, Zunino F.
    Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
    Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, Stoter G, Schellens JH.
    Cancer Chemother Pharmacol; 1998 Jun; 41(4):307-16. PubMed ID: 9488600
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.
    Cancer Res; 1996 Feb 01; 56(3):556-62. PubMed ID: 8564971
    [Abstract] [Full Text] [Related]

  • 7. Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.
    Anzai H, Frost P, Abbruzzese JL.
    Cancer Res; 1992 Apr 15; 52(8):2180-5. PubMed ID: 1373105
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
    Pawlik CA, Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Danks MK.
    Clin Cancer Res; 1998 Aug 15; 4(8):1995-2002. PubMed ID: 9717830
    [Abstract] [Full Text] [Related]

  • 10. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
    De Cesare M, Pratesi G, Perego P, Carenini N, Tinelli S, Merlini L, Penco S, Pisano C, Bucci F, Vesci L, Pace S, Capocasa F, Carminati P, Zunino F.
    Cancer Res; 2001 Oct 01; 61(19):7189-95. PubMed ID: 11585754
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B, Hansen HH, Høgdall C, Engelholm SA.
    Cancer; 2002 Oct 15; 95(8):1656-62. PubMed ID: 12365013
    [Abstract] [Full Text] [Related]

  • 12. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G.
    Clin Cancer Res; 1999 Apr 15; 5(4):909-16. PubMed ID: 10213228
    [Abstract] [Full Text] [Related]

  • 13. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
    Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F.
    Cell Growth Differ; 1999 Jul 15; 10(7):473-8. PubMed ID: 10437915
    [Abstract] [Full Text] [Related]

  • 14. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M, Benzo A, Irrissuto C, Lopez G, Curatella B, Maggi CA, Manzini S, Crea A, Caroli S, Cubadda F, Binaschi M.
    Cancer Chemother Pharmacol; 2008 Sep 15; 62(4):621-9. PubMed ID: 18038274
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G.
    Clin Cancer Res; 2000 May 15; 6(5):2053-63. PubMed ID: 10815932
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
    Saucier JM, Yu J, Gaikwad A, Coleman RL, Wolf JK, Smith JA.
    J Oncol Pharm Pract; 2007 Mar 15; 13(1):39-45. PubMed ID: 17621566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.